Skip to content
The Policy VaultThe Policy Vault

Afinitor Disperz — CareFirst (Caremark)

thymic carcinoma

Initial criteria

  • Single-agent therapy

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months